Skip to main content
See every side of every news story
Published • loading... • Updated

Will Phase III Colon Cancer Trial Change Akeso Stock Narrative

Summary by BizToc
Akeso completed a follow-on equity offering of 20,000,000 ordinary shares at HK$97.76 per share, raising about HK$1.96b, after recently reporting first patient dosing in a Phase III trial of cadonilimab in perioperative MSI H or dMMR colon cancer. The capital raise strengthens Akeso's funding…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

BizToc broke the news on Sunday, October 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal